SeaStar Medical Reports 69% Q1 Revenue Surge, Advances Adult AKI Trial with Breakthrough Status
ICU has more than doubled off its 52-week low of $2.07.
Summary
SeaStar Medical reported strong first-quarter financial results, with revenue increasing 69% year-over-year to $0.5 million driven by QUELIMMUNE product sales and an expanded customer base. Critically, the company provided significant business updates, including advancing enrollment in its NEUTRALIZE-AKI pivotal trial for adult acute kidney injury (AKI) and initiating efforts for a modular post-marketing application (PMA) submission for this indication, which has FDA Breakthrough Device Designation. This positive operational and clinical progress is material for the company, especially given the "substantial doubt" about its ability to continue as a going concern noted in its last 10-K. The adult AKI market is significantly larger than the pediatric market, making progress in this area a key future growth driver. Investors will be watching for continued enrollment updates for the NEUTRALIZE-AKI trial and further details on the PMA submission timeline.
At the time of this announcement, ICU was trading at $4.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $2.07 to $13.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.